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Abstract
Background: The bacterial genus Shigella is the leading cause of dysentery. There have been significant increases in the
proportion of Shigella isolated that demonstrate resistance to nalidixic acid. While nalidixic acid is no longer considered as a
therapeutic agent for shigellosis, the fluoroquinolone ciprofloxacin is the current recommendation of the World Health
Organization. Resistance to nalidixic acid is a marker of reduced susceptibility to older generation fluoroquinolones, such as
ciprofloxacin. We aimed to assess the efficacy of gatifloxacin versus ciprofloxacin in the treatment of uncomplicated
shigellosis in children.
Methodology/Principal Findings: We conducted a randomized, open-label, controlled trial with two parallel arms at two
hospitals in southern Vietnam. The study was designed as a superiority trial and children with dysentery meeting the
inclusion criteria were invited to participate. Participants received either gatifloxacin (10 mg/kg/day) in a single daily dose
for 3 days or ciprofloxacin (30 mg/kg/day) in two divided doses for 3 days. The primary outcome measure was treatment
failure; secondary outcome measures were time to the cessation of individual symptoms. Four hundred and ninety four
patients were randomized to receive either gatifloxacin (n = 249) or ciprofloxacin (n = 245), of which 107 had a positive
Shigella stool culture. We could not demonstrate superiority of gatifloxacin and observed similar clinical failure rate in both
groups (gatifloxacin; 12.0% and ciprofloxacin; 11.0%, p = 0.72). The median (inter-quartile range) time from illness onset to
cessation of all symptoms was 95 (66–126) hours for gatifloxacin recipients and 93 (68–120) hours for the ciprofloxacin
recipients (Hazard Ratio [95%CI] = 0.98 [0.82–1.17], p = 0.83).
Conclusions: We conclude that in Vietnam, where nalidixic acid resistant Shigellae are highly prevalent, ciprofloxacin and
gatifloxacin are similarly effective for the treatment of acute shigellosis.
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Introduction
Dysentery is an infection of the gastrointestinal tract
characterized by diarrhea containing blood and/or mucous,
abdominal cramping and tenesmus. The major cause of
dysentery is the bacterial genus Shigella. Humans are the only
known reservoir of Shigella, which are transmitted from person to
person by the fecal-oral route, the infectious dose is low [1], and
children under five years of age are at the greatest risk of
infection [2]. The precise burden of Shigellosis is difficult to
estimate, particularly in developing countries, as many cases go
unreported and accurate diagnosis relies on bacterial culture,
which is not always feasible or reliable. World Health
Organization (WHO) estimates in 1999 put the number of
cases at 164.7 million per year worldwide, with 99% of these
infections occurring in developing countries [3]. The WHO also
estimated that Shigellosis was responsible for over a million
deaths per year [4]. Shigella are endemic in Vietnam [5], and in
www.plosntds.org 1 August 2011 | Volume 5 | Issue 8 | e1264Nha Trang, in central Vietnam, an incidence of 490/100,000 in
children under five has been estimated [6].
Antimicrobials are routinely administered to Shigellosis patients
and correspond with clinical improvement [7,8], however, many
infecting organisms from various regions are now resistant to
multiple antimicrobials [9–11]. In southern Vietnam we have
recently documented a transition from S. flexneri to S. sonnei which
has been concurrent with a dramatic shift in antimicrobial
resistance patterns [12]. The majority (. 90%) of Shigella strains
we now isolate demonstrate resistance to nalidixic acid [12].
Whilst nalidixic acid is no longer considered as an effective
therapeutic agent for shigellosis, the fluoroquinolone, ciprofloxa-
cin, is the current recommendation of the WHO [4,13].
Ciprofloxacin is considered to be efficacious, cost effective and
generally safe for use in a pediatric population. However,
resistance to nalidixic acid generally correlates with a decreased
susceptibility to ciprofloxacin and other older generation fluoro-
quinolones [14]. Mutations within the DNA gyrase gene (gyrA), the
topoisomerase gene (parC) and multiple plasmid mediated
quinolone resistance (PMQR) determinants can elevate the
minimum inhibitory concentration (MIC) to ciprofloxacin, and
may hinder effective treatment [15]. In fact, some Shigella strains
that have been isolated from patients with dysentery have already
been reported as being resistant to ciprofloxacin, with an MIC .
0.25 mg/mL [16]. Alternative regimens are obviously needed for
those patients infection with organisms that may exhibit resistance
to ciprofloxacin.
Gatifloxacin is a fourth generation fluoroquinolone. It has a
broad spectrum of activity, with potent activity against many
gram-positive and gram-negative organisms [17]. Gatifloxacin has
been shown to be able be distributed extensively throughout
human tissues and can actively penetrate phagocytic cells in vitro
[18]. Significant intracellular accumulation means that gatiflox-
acin demonstrates bactericidal activity against susceptible intra-
cellular pathogens, such as Shigella [19]. Gatifloxacin has been
demonstrated to be highly efficacious in the treatment of enteric
fever caused by nalidixic acid resistant organisms in trials
performed in Nepal and Vietnam [20,21]. A differential binding
motif of gatifloxacin to the DNA gyrase (gyrA) with respect to
ciprofloxacin, means that this agent is less prone to the inhibition
induced by the common resistance associated mutations [15].
To date there very few published trials studying the efficacy of
fluoroquinolones in the treatment of shigellosis in children [22–24]
and we hypothesized that a therapy with gatifloxacin would be
effective in treating shigellosis, particularly in an area with a high
level of nalidixic acid resistance. We conducted a randomized
controlled trial (RCT) evaluating the efficacy of gatifloxacin versus
ciprofloxacin in pediatric patients with uncomplicated dysentery in
two locations in southern Vietnam where nalidixic acid resistant
Shigella predominate.
Materials and Methods
Trial registration
Controlled trials number ISRCTN55945881.
Ethical approval
This study was conducted according to the principles expressed
in the Declaration of Helsinki. This work was approved by the
institutional ethical review boards of the Hospital for Tropical
Diseases, Ho Chi Minh City, Huu Nghi Hospital, and The Oxford
Tropical Research Ethics Committee (OXTREC) (number 010–
06 (2006)), United Kingdom. The parent or guardian of all
enrollees was required to provide written informed consent prior
to entrance into the study.
Trial design
An open label randomized comparison of gatifloxacin (10 mg/
kg/day once-a-day orally) for 3 days versus ciprofloxacin (30 mg/
kg/day in twice-a-day orally) for 3 days for the treatment of
uncomplicated bacillary dysentery in children. This trial was
design to demonstrate the superiority of gatifloxacin over
ciprofloxacin.
Study participants
The study physicians enrolled patients who were admitted to
Pediatric Ward B, The Hospital for Tropical Diseases, Ho Chi
Minh City, Vietnam or the Department of Infectious Diseases,
Huu Nghi Hospital, Cao Lanh, Dong Thap, Vietnam from June
22
nd, 2006 to March 13
th, 2009. The study included children
under the age of 15 years with a history of passing bloody or
mucoid stools, with or without abdominal pain, tenesmus or fever
(defined as a temperature .37.8uC) for less than 72 hours prior to
admission. Exclusion criteria were any signs of a severe infection,
including shock, jaundice, extensive gastrointestinal bleeding, a
previous history of hypersensitivity to either of the trial drugs,
known previous treatment with any (fluoro) quinolone during the
current bout of disease prior to hospital admission, or a coexisting
infection requiring antimicrobial therapy. Additionally, all chil-
dren that had a trophozoite or Entamoeba histolytica present in their
stool on microscopic examination were excluded from enrolment.
Study intervention
Each patient recruited into the study was randomized to receive
one of two regimens, treatment with either gatifloxacin (Stada
pharmaceuticals, Vietnam) 10 mg/kg/day in a single daily dose
for 3 days or treatment with ciprofloxacin (OPV manufacturer,
Vietnam) 30 mg/kg/d in two divided doses for 3 days. Other
treatments, including fluid (ORS, parenteral) and antipyretics
(paracetamol) were given to enrollees in both groups according to
Author Summary
The bacterial genus Shigella is the most common cause of
dysentery (diarrhea containing blood and/or mucus) and
the disease is common in developing countries with
limitations in sanitation. Children are most at risk of
infection and frequently require hospitalization and
antimicrobial therapy. The WHO currently recommends
the fluoroquinolone, ciprofloxacin, for the treatment of
childhood Shigella infections. In recent years there has
been a sharp increase in the number of organisms that
exhibit resistance to nalidixic acid (an antimicrobial related
to ciprofloxacin), corresponding with reduced susceptibil-
ity to ciprofloxacin. We hypothesized that infections with
Shigella strains that demonstrate resistance to nalidixic
acid may prevent effective treatment with ciprofloxacin.
We performed a randomized controlled trial to compare 3
day ciprofloxacin therapy with 3 days of gatifloxacin, a
newer generation fluoroquinolone with greater activity
than ciprofloxacin. We measured treatment failure and
time to the cessation of individual disease symptoms in
249 children with dysentery treated with gatifloxacin and
245 treated with ciprofloxacin. We could identify no
significant differences in treatment failure between the
two groups or in time to the cessation of individual
symptoms. We conclude that, in Vietnam, ciprofloxacin
and gatifloxacin are similarly effective for the treatment of
acute dysentery.
Gatifloxacin versus Ciprofloxacin in Shigellosis
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diazepam (OPV manufacturer, Vietnam) 0.25 mg/kg intrave-
nously. No additional anti-diarrheal drugs, including smectite,
loperamide or probiotics were permitted or used.
Study procedures
On admission (study day 0), a detailed history of the present
illness was documented on a standard report form which recorded
the duration of illness prior to admission to hospital (days), the
presence of fever (defined as a prolonged temperature . 37.8uC),
abdominal discomfort, vomiting, bloody or mucoid diarrhea
(defined as $3 loose stools with obvious blood or mucus),
estimated number of episodes of diarrhea before attending
hospital, convulsions believed to be related to fever and/or
infection and the administration of any known pre-treatment with
antimicrobials and or other treatment. Baseline data including age
(in months), sex, location of residence and weight (kg) were also
collected.
A physical examination was performed on admission and daily
thereafter until discharge. Particular note was taken of any bone or
joint symptoms. The axillary temperature, pulse rate, respiratory
rate, blood pressure, and frequency and character of stools were
recorded every six hours. A full blood cell count was performed on
all patients and stools were examined by microscopy (HPF (6400))
to identify parasites, and to count white blood cells and red blood
cells; the cell counts were scored on scale from zero to three, scale
0 = 0 cells/HPF, scale 1 = 1 to 10 cells/HPF, scale 2 = 11 to 20
cells/HPF, scale 3 = 21 to 30 cells/HPF and scale 4 = .40 cells/
HPF. A blood sample was taken on Day 0 (on enrolment) and on
day 3 (at the same time at the blood sample on Day 0) and glucose
test was performed on those in the gatifloxacin group to assess any
potential dysglycemia (hypoglycemia or hyperglycemia) in this
portion of the study population over the duration of the therapy.
Time from initial investigation in hospital to the cessation of
bloody/mucoid and watery diarrhea (in hours) was recorded.
Duration of hospital stay was recorded in days post admission;
patients were only discharged when all clinical symptoms had
resolved completely.
Enrolled patients were additionally required to attend a follow
up visit, which was scheduled at seven days after discharge. During
the follow up visit, the parents or guardians of the enrolled were
questioned about their general health after discharge. Data
regarding shigellosis-related symptoms were recorded in standard
report form and a stool sample was collected for microbiological
culture.
Microbiological methods
Patients stool samples were cultured overnight in selenite F
broth (Oxoid, Basingstoke, UK) and onto MacConkey and XLD
agar (Oxoid) at 37uC. Colonies suggestive of Salmonella or Shigella
(non-lactose fermenting) were sub-cultured on to nutrient agar and
were identified using a ‘short set’ of sugar fermentation reactions
(Klinger iron agar, urea agar, citrate agar, SIM motility-indole
media (Oxoid)). After incubation for 18–24 h at 37uC, the test
media were read for characteristic Shigella reactions and API 20E
test strips of biochemical reactions (Biomerieux, Paris, France)
were used to confirm the identity of Shigella spp. Serologic
identification was performed by slide agglutination with polyvalent
somatic (O) antigen grouping sera, followed by testing with
available monovalent antisera for specific serotype identification as
per the manufacturers recommendations (Denka Seiken, Japan).
Antimicrobial susceptibility testing of all Shigella isolates against
nalidixic acid (NAL), ciprofloxacin (CIP) and gatifloxacin (GAT)
was performed by disk diffusion following standardized Clinical
and Laboratory Standards Institute methods [25]. The minimum
inhibitory concentrations (MICs) were additionally calculated for
all isolates by E-test, according to manufacturer’s recommenda-
tions (AB Biodisk, Solna, Sweden) and were compared to control
strain E. coli ATCC 25922 and an in house fully sensitive E. coli
control. Isolates were stored on Protect beads (Prolabs, Oxford,
United Kingdom) at 270uC.
Primary endpoints
The pre-defined primary endpoint of this study was the
composite endpoint of in-hospital treatment failure defined as
the occurrence of any clinical or microbiological treatment failure
(or both). A clinical treatment failure was defined as fever ($
37.8uC), or the persistence of any signs or symptoms of the disease.
These symptoms were defined as vomiting, abdominal pain or
tenesmus with or without $3 loose stools with our without blood,
mucus or blood and mucus after 120 hours of start of either
treatment. Clinical treatment failures were subsequently treated
with ceftriaxone at 50 mg/kg/day intravenously in single doses for
3 days at the discretion of the treating physician. A microbiological
treatment failure was defined as a positive stool culture for the
original infecting pathogen after the antimicrobial course was
complete (day 3 of treatment or later).
Secondary endpoints
The secondary endpoints were defined to describe the time
from study enrolment (i.e. from the first dose of study treatment)
until resolution of specific symptoms. As Shigellosis can be self-
limiting, the time to cessation of all symptoms was additionally
calculated from the time of disease onset, i.e. accounting for the
duration of disease prior to hospital admission. The secondary
endpoints were fever clearance time (FCT), i.e. time until the
temperature was for the first time #37.8uC and subsequently
remained #37.8uC for at least 48 hours; bloody diarrhea
clearance time (BDCT), i.e. time until the first non-bloody stool
recorded; diarrhea clearance time (DCT), i.e. time until the first
non-diarrheal stool was recorded; and total duration of illness, i.e.
the time till cessation of all symptoms. The follow-up visit was
scheduled to occur 7 days after hospital discharge and information
at this time point was not deemed to be as quantifiable as
outcomes during hospitalization and, therefore, was not included
in the primary outcome but the proportion of patients with failure
at the follow-up visit (overall combined failure, diarrhea and other
symptoms of shigellosis) was reported as a secondary endpoint.
Sample size
This trial was designed as a superiority trial of gatifloxacin
versus ciprofloxacin with the hypothesis that in patients with
Shigella positive stool culture, gatifloxacin reduces the proportion of
patients failing treatment from 25% to 5%. To detect such a
reduction with 80% power at the two-sided 5% significance level,
each group required 58 culture confirmed enrollees. We estimated
the rate of Shigella positive stool culture to be approximately 33%
of all children with bloody of mucoid diarrhea and the dropout
rate to be approximately 5% and thus aimed to enroll a total of
366 cases with acute dysenteric syndrome. However, when 366
cases had been enrolled, only 80 culture positive patients with
Shigella were identified (culture rate 22%), and the study was
extended to enroll 134 more cases (500 in total). When 500
patients had been enrolled, 107 cases were stool culture positive
for Shigella. Because of time and budget limitations, recruitment
was terminated at 500. Of note, the original sample size
calculation was based on a conservative sample size formula; a
more precise power estimate based on simulation revealed that the
Gatifloxacin versus Ciprofloxacin in Shigellosis
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Shigella patients was 81%.
Randomization
Patients were randomly allocated to one of two treatments. An
administrator otherwise not involved in the trial performed
randomization in blocks of 10. The random allocations were
placed in sealed opaque envelopes, which were opened once the
patient was enrolled into the trial after meeting the inclusion and
exclusion criteria. Consecutive patients who presented to the clinic
and were eligible to be enrolled were randomized and enrolled in
the same sequence as they presented. Blinding was not carried out
in this trial due to different frequencies of administration and other
logistical reasons.
Statistical methods
The proportion of patients reaching the primary endpoint of
overall treatment failure and its components, respectively, were
compared between the two arms using x
2-tests (p-values were
calculated by Monte Carlo simulation if the expected count in any
cell was ,5) and 95% confidence intervals for absolute risk
differences were calculated according to the method of Agresti and
Caffo [26].
We analyzed the secondary time-to-event endpoints using survival
methodsandcomparisonswerebasedonCoxregressionmodelswith
treatment as the sole covariate. We also summarized the proportion
of patients with failure at the follow-up visit as for the primary
endpoint. Only patients who attended the follow-up visit were
included, i.e. we did not perform any imputation of missing data.
The main analysis population included all patients who received
at least one dose of the intervention analyzed according to the
randomized treatment group (intention-to-treat) and analyses were
repeated in the per-protocol population, which included only
Shigella spp. stool culture positive patient. In addition, the primary
endpoint was analyzed in the subgroups defined by the following
grouping criteria: culture positive vs. negative, Shigella pathogen vs.
Salmonella pathogen and Nalidixic acid sensitive Shigella vs.
Nalidixic acid resistant Shigella. Heterogeneity of the treatment
effect was tested with a likelihood ratio test based on a logistic
regression model that included an interaction between treatment
effect and the sub-grouping criteria. P-values for two-sided tests
and 95% confidence intervals are reported throughout. All
analyses were performed with the statistical software R version
2.9.1 (R Foundation for Statistical Computing, Vienna, Austria,
www.r-project.org.)
Results
Study participant flow
Between June 22
nd, 2006 and March 13
th, 2009 551 pediatric
patients hospitalized with acute dysentery were assessed for
enrolment in this RCT. The flow chart of the trial is presented
in Figure 1, and shows that out of the eventual 500 enrolled
patients randomized (300 at Huu Nghi Hospital, Dong Thap and
200 at the Hospital for Tropical Diseases), 494 received at least
one dose of either treatment, corresponding with 245 patients in
the ciprofloxacin group and 249 patients in the gatifloxacin group.
Baseline information
The baseline characteristics of the intention to treat patients
(ITT) are shown in Table 1. The median age of the 494 patients in
the intention-to-treat population (ITT) was 19 months, with a range
of 2 to 144 months, 58.9% were Male. Patients had a median
duration ofdysenterypriortoadmissionof24 hours, with arange of
1 to 72 hours. The most common clinical observation was fever, as
87.4% of patients had a temperature . 37.8uC at randomization.
Fortytwopoint five percent (n = 210)ofpatientswere enrolled with
a history of blood in their stools and 57.5% of enrollees (n = 284)
had a history of mucus without blood in their stools. Baseline
characteristics, in particular disease severity (signified by blood in
the stool, number of diarrheal episodes, fever, vomiting and
abdominal pain), were comparable in both groups (Table 1).
There were more patients with a bacterial pathogen positive
stool culture in the gatifloxacin group (n = 86, 34.5%) than in the
ciprofloxacin group (n = 63, 25.7%), of which 61 and 46 were
Shigella spp. respectively. Sixty seven point three percent (n = 72)
of the Shigella isolated were resistant to nalidixic acid (MIC
$16 mg/ml), additionally, the same proportion (n = 72) of Shigella
isolates were S. sonnei, 33 were S. flexneri and 2 were S. boydii.
Study endpoints and outcomes
Results for the primary and secondary endpoints in the ITT
population are shown in Table 2. The primary endpoint (composite
overall treatment failure), demonstrated that fifty-seven (11.5%) of all
ITT patients failed treatment,of which,30 were in gatifloxacin group
and 27 were in ciprofloxacin group (p = 0.72). The majority of
patients that failed therapy had clinical failure, which was principally
associated with persistent diarrhea for longer than 120 hours after
initiating treatment. There were four patients with prolonged fever
and nine with microbiological failures in the ciprofloxacin group and
six microbiological failures in the gatifloxacin group. There were no
significant difference in secondary endpoints related to time to
resolution of symptoms (Table 2).
In the per-protocol analysis (Shigella spp. stool culture positive
patients), the risk of treatment failure was as 4/61 (6.6%) for
gatifloxacin and 5/46 (10.9%) for ciprofloxacin (p = 0.49). Three
out of sixty one (4.9%) and 2/46 (4.3%) in the gatifloxacin group
and the ciprofloxacin group, respectively, had persistent diarrhea
for longer than 120 hours post treatment. In the per-protocol
analysis, the time to resolution of symptoms was also similar in the
gatifloxacin and ciprofloxacin groups, respectively: time from
study enrolment to fever clearance (median 18 vs. 18 hours, p =
0.45) or bloody diarrhea clearance (median 24 vs. 24 hours, p =
0.74) and total illness duration (median duration from illness onset
77 vs. 71 hours, p = 0.48). The risk of overall treatment failure in
selected subgroups is displayed in Table 3, which shows no
evidence of treatment effect heterogeneity.
The proportion of patients that attended the follow up health
visit was 87.4%. None of the 17 (3.9%) patients attending follow
up which still demonstrated evidence of disease had a Shigella spp.
positive stool culture, yet 15 (3.5%) still had persistent diarrhea
(Table 2). There was no significant difference in prolonged
symptoms synonymous with dysentery between the two study
groups in the ITT analysis or the PP analysis.
Adverse events
There is a concern about the use of gatifloxacin, as it has been
associated with dysglycemia (hypoglycemia and hyperglycemia) in
elderly adults (both diabetic and non-diabetic) [27]. We compared
the blood glucose levels to detect dysglycemia on day zero (prior to
the first dose) (n = 244) and on day three (blood sample taken on
same time of day as the primary sample) (n = 234) in patients in
gatifloxacin group. On day zero, 180/244 (73.8%) had normal
blood glucose (65–115 mg/dl), 49/244 (20%) had mild hypergly-
cemia (116–160 mg/dl), 6/244 (2.5%) had moderate hyperglyce-
mia (161–250 mg/dl), 5/244 (2%) had mild hypoglycemia (55–
64 mg/dl) and 4/244 (1.6%) had moderate hypoglycemia (40–
54 mg/dl). On Day three, 193/234 (82.5%) had glucose within
Gatifloxacin versus Ciprofloxacin in Shigellosis
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(2.1%) had moderate hyperglycemia and 3/234 (1.3%) had mild
hypoglycemia. Paired glucose data were for 234 patients treated
with gatifloxacin, the means of blood glucose levels on day zero
and day three were 100.7 mg/dl and 98.4 mg/dl, respectively (p
= 0.18; 2 tailed t-test). There were limited number of non-severe
events, these included, one patient in the gatifloxacin arm with
night sweats and 18 children vomiting after taking the medication
(12 in ciprofloxacin group and 6 in the gatifloxacin group). In the
case of vomiting the treatment drug were re-administered one
hour after the vomiting episode. There was no death or severe
clinical complications during the course of the trial. The clinical
status of two children (one in each group) after three days of the
study treatments warranted the use of intravenous ceftriaxone.
Discussion
Shigellosis remains a common infection in low and medium
human index countries and in countries undergoing industrializa-
tion with areas of inadequate sanitation [28]. In the pediatric
proportion of the population that suffers shigellosis an effective
antimicrobial remains important for the management of infection.
Despite shigellosis being self-limiting, antimicrobials are generally
considered to be associated with clinical improvement and a
shortened duration of disease. The findings of a recent Cochrane
review support antimicrobial use in Shigella infections, although the
overall strength of data on antimicrobial therapy for shigellosis is
weakand requiresfurtherconsideration[29].Onepotentialeffect of
a suitable antimicrobial therapy for all Shigella patients is reducing
fecal carriage of the organisms after infection, thus reducing
transmission to close contacts, such as household members or
children attending the same day-care setting [7,23,24].
A three day course of ciprofloxacin is the treatment currently
recommended by the WHO for shigellosis, including S. dysenteriae
type 1 infections [13]. In the study presented here, 494 children
hospitalized for acute dysentery (in which 107 cases had a Shigella
positive stool culture) were treated by either current WHO
recommendations, or three days of one daily dose of oral
Figure 1. Profile for the gatifloxacin versus ciprofloxacin shigellosis treatment trial. The CONSORT flow diagram showing the flow of
participants throughout the trial.
doi:10.1371/journal.pntd.0001264.g001
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gatifloxacin. Rather, it showed a similar efficacy of both drugs in
the treatment of childhood dysentery, including those with a stool
culture confirmed Shigella infection. However, gatifloxacin has a
longer half-life than ciprofloxacin and the once-a-day administra-
tion may be considered a little more convenient than twice-a-day
regime of ciprofloxacin. In total, 67.3% of Shigella strains isolated
were nalidixic acid resistant, but both antimicrobials appeared to
clear Shigella from stools equally effectively (as tested by
microbiological culture).
Our work has some caveats, firstly, blinding was not performed
due to financial limitations and differing regimens, thus there was the
potential of introducing investigator bias, yet, this was minimal due as
result of the randomization process. Secondly, the primary endpoint
was a composite endpoint of both clinical symptoms and microbi-
ological failure, which was deemed more appropriate due to the
natureof the infection. Furthermore, it was not possible to identify an
infecting agent in the majority of cases, and we know from our
currently unpublished work that more than one etiological agent may
cause the infection. Therefore, whilst cessation of symptoms is the
Table 1. The baseline characteristics and clinical symptoms of 494 intention-to-treat patients whom received an intervention.
Patient Characteristic All patients (n = 494) Gatifloxacin (n = 249) Ciprofloxacin (n = 245)
Details
Age (months) 19 (10.1–32) 19 (10–31) 19 (11–33)
Male sex 291 (58.9%) 143 (57.4%) 148 (60.4%)
Weight (Kg) 10 (8.2–12) 10 (8.2–12) 10 (8.4–12)
Height (cm) 78.5 (70–88) 78 (70–87) 79 (70–89)0
Nutritional status
Overweight 4 (0.8%) 1 (0.4%) 3 (1.2%)
Normal 363 (73.5%) 187 (75.1%) 176 (71.8%)
Malnutrition I 93 (18.9%) 47 (18.9%) 46 (18.8%)
Malnutrition II 29 (5.9%) 13 (5.2%) 16 (6.5%)
Malnutrition III 5 (1%) 1 (0.4%) 4 (1.6%)
Clinical observations prior on admission
Illness duration prior to admission (hrs) 24 (16.3–48) 24 (16–48) 24 (18–48)
Fever ($37.8uC) 429 (87.4%) 215 (87.4%) 214 (87.4%)
History of febrile convulsions 40 (8.1%) 19 (7.6%) 21 (8.6%)
History of diarrhea with blood 210 (42.5%) 107 (43%) 103 (42%)
History of mucoid diarrhea without blood 284 (57.5%) 142 (57%) 142 (58%)
Vomiting 204 (41.3%) 91 (36.6%) 113 (46.1%)
Abdominal pain 365 (74.2%) 188 (75.8%) 177 (72.5%)
Tenesmus 339 (69.2%) 173 (70%) 166 (68.3%)
Clinical observations within 24 hours of admission
Mucoid diarrhea without blood 370 (74.9%) 193 (77.5%) 177 (72.2%)
Mucoid Diarrhea (number in 24 hr period) 3 (0–6) 3 (1–6) 3 (0–6)
Diarrhea with blood 445 (90.1%) 224 (90%) 221 (90.2%)
Bloody Diarrhea (number in 24 hr period) 1 (1–5) 1 (1–5) 2 (1–5)
Maximum number of episodes in 24 hr period 6 (3–10) 6 (3–10) 6 (3–9)
White blood cells in stool
1
0 214 (44.7%) 111 (45.1%) 103 (44.2%)
+1 79 (16.5%) 42 (17.1%) 37 (15.9%)
+2 42 (8.8%) 17 (6.9%) 25 (10.7%)
+3 104 (21.7%) 56 (22.8%) 48 (20.6%)
+4 40 (8.4%) 20 (8.1%) 20 (8.6%)
White blood cell count 11,290 (8,530–14,900) 11,100 (8,530–14,200) 11,450 (8,572–15,600)
Pathogen isolated
Shigella 107 (21.7%) 61 (24.5%) 46 (18.8%)
Nalidixic acid resistant Shigella 72 (14.6%) 40 (16.1%) 32 (13.1%)
Salmonella 40 (8.1%) 25 (10%) 15 (6.1%)
Other 2 (0.4%) 0 (0%) 2 (0.8%)
Summary statistics are absolute counts (%) for categorical variables and medians (IQR) for continuous data.
1White blood cells in stool 0; 0 cells/HPF, 1; 1 to 10 cells/HPF, 2; 11 to 20 cells/HPF, 3: 21 to 30 cells/HPF and 4; .30 cells/HPF.
doi:10.1371/journal.pntd.0001264.t001
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patient) for shigellosis, it may be difficult to assess accurately and
consistently. We cannot rule out that the persistence of symptoms
may be caused by an additional infecting pathogen. Finally, it would
be difficult to conduct such a trial in the community in this setting,
etiological diagnostics for diarrheal disease are not routinely
performed in this location and we are uncertain of the burden of
shigellosis in the community. Our study may represent the most
severe end of the disease spectrum for shigellosis, yet it is these
individuals that may require the most apposite antimicrobial therapy.
Our data show similar overall risks of treatment failure in the
two treatment groups (11% in the ciprofloxacin group versus 12%
in gatifloxacin group). The overall risk of treatment failure rate of
8.4% in culture confirmed shigellosis cases is considerably lower
than the 31% to 35% reported in the treatment of dysentery in a
2002 study [30]. This disparity in failure rate may be reflected by a
difference in the principal Shigella serotype isolated. The most
commonly isolated Shigella species here was S. sonnei, whilst S.
dysenteriae was the most common isolated in the aforementioned
2002 study. S. dysenteriae causes a considerably more severe
syndrome than S. sonnei, which is largely associated with the
secretion of shiga toxin [31]. In an additional shigellosis treatment
trial, the failure rate in adults treated with ciprofloxacin was 18%
[32]. In dysentery treatment trial conducted in Ho Chi Minh City,
Table 2. Primary and secondary trial endpoints.
Parameter
All patients
(n = 494)
1
Gatifloxacin
(n = 249)
1
Ciprofloxacin
(n = 245)
1
Comparison:
Estimate (95% CI)
2 p-value
3
Primary endpoint
Overall Treatment Failure 57 (11.5%) 30 (12.0%) 27 (11.0%) 1.0 (24.7 to 6.7) 0.72
b) Clinical Failure 45 (9.1%) 26 (10.4%) 19 (7.8%) 2.7 (22.5 to 7.8) 0.30
Symptom . 5 days failure 13 (2.6%) 8 (3.2%) 5 (2.0%) 1.2 (21.8 to 4.2) 0.42
Fever failure 4 (0.8%) 0 (0%) 4 (1.6%) 21.6 (3.5 to 0.3) 0.06
b) Microbiological Failure 15 (3.0%) 6 (2.4%) 9 (3.7%) 21.3 (24.5 to 1.9) 0.41
Secondary endpoints
4
Fever clearance time (hrs) 12 (0–30) 12 (0–30) 12 (0–28) 1.00 (0.84 to 1.20) 0.98
Bloody diarrhea clearance time (hrs) 24 (17–48) 24 (17–47) 25 (17–48) 1.11 (0.93 to 1.32) 0.26
Diarrhea clearance time (hrs) 61 (40–90) 61 (41–92) 61 (38–90) 0.98 (0.82 to 1.17) 0.84
Total time of illness from study enrolment (hrs) 64 (42–92) 64 (42–93) 64 (41–90) 0.99 (0.83 to 1.18) 0.90
Total time of illness from illness onset (hrs) 95 (66–123) 95 (66–126) 93 (68–120) 0.98 (0.82 to 1.17) 0.83
Follow up
Patients attending follow up (n) 432 (87.4%) 217 (87.1%) 215 (88.8%) - -
Diarrhea on follow up (n) 15 (3.5%) 8 (3.7%) 7 (3.3%) 0.4 (23.2 to 4.1) 0.81
Other symptom on follow up (n) 2 (0.5%) 2 (0.9%) 0 (0%) 0.9 (20.9 to 2.7) 0.51
Failure on follow up (n) 17 (3.9%) 10 (4. 6%) 7 (3.3%) 1.4 (22.5 to 5.2) 0.47
1Summarized as n (%) for proportion data and median (IQR) for time-to event data.
2Estimate corresponds to the absolute risk difference (in%) for proportion data and a hazard ratio for time-to-event data.
3p-values calculated by chi-squared test for proportional data and by Cox Regression models for time-to-event data.
4Time-to-event endpoints calculated from study enrolment (i.e. the first dose of study treatment) unless mentioned otherwise.
doi:10.1371/journal.pntd.0001264.t002
Table 3. Overall treatment failure in subgroups.
Subgroup
Gatifloxacin
failures (n)
Ciprofloxacin
failures (n) RD (95% CI), p-value
1
p-value for
heterogeneity
2
Population
Culture positive
Culture negative
17/86 (19.8%)
13/163 (8.0%)
16/63 (25.4%)
11/182 (6.0%)
25.6 (219.3 to 7.9); p = 0.41
1.9 (23.6 to 7.5); p = 0.48
0.28
Pathogen
3
Shigella
Salmonella
4/61 (6.6%)
13/25 (52.0%)
5/46 (10.9%)
9/15 (60.0%)
24.3 (216.1 to 6.9); p = 0.50
28.0 (237.0 to 23.1); p = 0.62
0.81
Nalidixic acid resistance
4
Resistant Shigella
Sensitive Shigella
2/40 (5.0%)
2/20 (10.0%)
4/32 (12.5%)
1/13 (7.7%)
27.5 (221.8 to 6.7); p = 0.39
2.3 (222.1 to 22.7); p =1 . 0
0.70
1RD = absolute risk difference (%).
2Heterogeneity was tested with a likelihood ratio test based on a logistic regression model that included an interaction between treatment effect and subgroup.
3Two patients with Pleisiomonas and Morganella infections (both in the ciprofloxacin group) are not included.
4Nalidixic acid resistance status was not available for two patients with Shigella infections.
doi:10.1371/journal.pntd.0001264.t003
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fluoroquinolone, ofloxacin, was comparable to our current data, at
10% [24]. A possible explanation for a reduced treatment failure
rate, despite a pattern of reduced susceptibility to fluoroquino-
lones, is that shigellosis caused by S. sonnei is gradually becoming a
more benign infection, an opinion that is shared by others [33].
Alternatively, due to improvements in education and healthcare,
patients are now admitted to hospital earlier. Therefore, case
management has improved and children receive therapy more
rapidly after the onset of symptoms. Here, we observed similar
failure rates in both treatment groups, despite a relationship
between nalidixic acid resistance and reduced susceptibility to
ciprofloxacin. These data suggest that whilst there has been a
notable increase in MIC to nalidixic acid in Shigella in Vietnam
over the last ten years, it may not yet be substantial enough to
hinder the bactericidal effect of ciprofloxacin in vivo. A similar
effect of both antimicrobial agents, despite gatifloxacin having
greater in vivo activity supports the theory of a less severe infection,
which may not, in all cases, require an antimicrobial for the
cessation of symptoms. Alternatively, Shigella may respond in
atypical manner to gatifloxacin, which respect to other Gram-
negative organisms, and mutations in the gyrA and parC gene may
have a greater effect on reducing the potency of the antimicrobial
agent.
The use of fluoroquinolones in children has been contraindi-
cated for many years because of the fear of arthropathy, however
there is limited evidence to support this theory. A two year of
follow-up of children treated with a short course ciprofloxacin or
ofloxacin for typhoid fever in Vietnam did not find any adverse
effects on growth and there was no evidence or arthropathy [34].
A more recent study conducted in a sheep model showed that
neither ciprofloxacin nor gatifloxacin affected growth velocity
when administered with using dosing regimen suitable for children
[35]. The WHO, after considering the risks and the benefits, has
recommended ciprofloxacin as the primary treatment of shigellosis
in adults and children [13], our data suggests that this choice
remains effective and we consider fluoroquinolones safe for use in
the pediatric population. Gatifloxacin is an effective treatment
against many Gram-negative infections, yet was voluntarily
withdrawn from the US and Canadian drug market in May
2006 because of concerns about severe glucose disturbances.
Reports of gatifloxacin related hypoglycemia and hyperglycemia
in clinical trials are rare, yet severe dysglycemic events (mainly
involved elderly patients with diabetes) were reported and
discussed in the medical literature during the post-marketing
period [27,36,37]. To date, clinically relevant dysglycemia has not
been reported in young adults or in children treated with
gatifloxacin [38,39], we found no evidence of dysglycemia in the
gatifloxacin treatment group. Treatment options for many Gram-
negative infections in developing countries, including Shigella are
clearly becoming increasingly limited. Gatifloxacin is a highly
efficacious antimicrobial for the treatment of many gastrointestinal
infections in the young and otherwise healthy patients and should
be available for such indications in locations (i.e. in industrializing
countries) where these diseases are endemic. However, in view of
the potential risk of dysglycemia, it may be prudent to not treat
patients over 50 years of age or with additional co-morbidities with
such infections with gatifloxacin.
Our data demonstrate that despite a substantial increase in the
number of organisms demonstrating resistance to nalidixic acid in
the preceding years, ciprofloxacin remains an effective therapy for
acute bacterial dysentery. Furthermore, we demonstrate that
gatifloxacin is similarly effective as ciprofloxacin in the cessation of
symptoms of shigellosis. Our current knowledge of the mecha-
nisms and the global distribution of Shigella with reduced
susceptibility to older fluoroquinolones (ciprofloxacin and ofloxa-
cin) remain limited and require further investigation. We conclude
that in locations where nalidixic acid resistant Shigellae are highly
prevalent, ciprofloxacin and gatifloxacin are similarly effective for
the treatment of acute shigellosis.
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